ETOPOSIDE
B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the B Acute Lymphoblastic Leukemia/Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Institute of Hematology & Blood Diseases Hospital, China | Phase 2/3 | B |
cd180 cart Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | CC |
sup19 car-t Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | CC |
Baffr Car-T Guangzhou Bio-gene Technology Co., Ltd | Early Phase 1 | C |
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →